Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Curacyte scientists discover new anti-tumour agents

17.06.2003


Curacyte AG, a Munich-based drug development company focused on novel treatments of inflammatory diseases, thrombotic disorders and cancer has announced today that its scientists have discovered a series of novel small molecule inhibitors of matriptase, a trypsin-like serine protease. Matriptase is an important mediator in the degradation of the extracellular matrix, a process which plays a key role during metastasis. Inhibiting this key enzyme produced by tumor cells might provide a route to prevent tumor metastasis and invasive growth. This compound series thus offers potential as novel anti-tumor agents for the treatment of metastatic malignancies and Curacyte will now move this program into pre-clinical development.



Since the discovery of the gene in 1999, matriptase has increasingly gained attention as a potential biological target for inhibiting tumor spread. Today, matriptase is recognized as an innovative anti-cancer target. In in vitro assays, the Curacyte inhibitor series exhibit excellent affinity and selectivity towards the target and a pharmacokinetic profile that supports their use as pharmaceutically active substances.

Dr. Helmut Giersiefen, Chief Executive Officer of Curacyte AG, commented on the recent scientific success:


"The discovery of the matriptase inhibitors corroborates the validity and value of our protease technology. Based on our proprietary inhibitor libraries and our competence with respect to the chemistry of these substances, we have identified a series of novel potential anti-tumor agents, enabling us to move another important project into preclinical development. We will continue to derive therapeutically valuable applications from our protease technology that we can leverage with pharmaceutical partners."

Curacyte pursues the development of its protease technology in close collaboration with the Center of Vascular Biology and Medicine of the University of Jena (Germany) under the leadership of Dr. Jörg Stürzebecher, a well-known pioneer in the area of synthetic inhibitors of serine proteases.

"We are very proud of our collaboration with Curacyte," commented Dr. Stürzebecher. "The successful development of these matriptase inhibitors was possible by combining our knowledge of the structure-function relationship of protease inhibitors that we gained over decades with the competence in drug discovery and pharmaceutical development provided by Curacyte. Our collaboration on protease inhibitors, including matriptase has been ongoing for over two years and establishes a benchmark for the fruitful synergies that can be created by bringing together academic and commercial competencies."

Sue Charles | alfa
Further information:
http://www.curacyte.com

More articles from Health and Medicine:

nachricht Monitoring the heart's mitochondria to predict cardiac arrest?
21.09.2017 | Boston Children's Hospital

nachricht Highly precise wiring in the Cerebral Cortex
21.09.2017 | Max-Planck-Institut für Hirnforschung

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Comet or asteroid? Hubble discovers that a unique object is a binary

21.09.2017 | Physics and Astronomy

Cnidarians remotely control bacteria

21.09.2017 | Life Sciences

Monitoring the heart's mitochondria to predict cardiac arrest?

21.09.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>